YOU ARE HERE PUBLICSCIENTIST WEBSITE

Other events

Epigenetics in Drug Discovery 2017

Monday 06 March 2017 - Tuesday 07 March 2017

Venue:   Cambridge, UK

Contact:   This email address is being protected from spambots. You need JavaScript enabled to view it.

SelectBio_logo_greybox_RGB-720x210

SELECTBIO is thrilled to announce the continuation of Epigenetics in Drug Discovery for 2017. The event will be one of four tracks within the multi-track conference, Advances in Drug Discovery. Registered delegates will have unrestricted access to all conference tracks and networking opportunities.

Attracting researchers from both academia and industry, EDD will explore the latest opportunities and challenges for epigeneticists looking to discover and develop new molecular entities.

Topics to be addressed include, assays for Methyltranferases and Demethylases, Bromodomain inhibitor discovery, indications beyond cancer, Non-BET Bromodomains and of course updates in Oncology. The agenda is available to view on the website.

If you work in epigenetics research, you will benefit from the expert knowledge of academic and industry leaders who are pushing the boundaries of drug discovery, whilst networking with the technology providers who are enabling them to do so.

Present your research on a poster while attending the meeting. Poster Submission Deadline: 20 February 2017.

Visit the website for up-to-date information, including details of our 3 for 2 offer on registration! Early bird – Register by 3 February 2017.

 
Learn more

News flash

Missing link in epigenetics could explain conundrum of disease inheritance

08-07-2016 - All News

The process by which a mother’s diet during pregnancy can permanently affect her offspring’s attributes, such as weight, could be strongly influenced by genetic variation in an unexpected part of...

Epigenetic switch for obesity

08-02-2016 - All News

Obesity can sometimes be shut down It is well known that a predisposition to adiposity lies in our genes. A new study by researchers at the Max Planck Institute of Immunobiology...